

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 1 2024
01/01/2024 – 31/03/2024

NSW Office for Health and Medical Research

Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> • Study Type = All • Application Type = Greater than low risk • Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	<ul style="list-style-type: none"> • Application Type = Low and negligible risk • Approval Type = Not within the reporting period • Migrated studies
Total	Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 1 2024**) are shown in **Table 1**.

During the reporting period, 209 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 209 studies, 84 (40%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

Ethics Approval (Q1 2024)						
All greater than low risk applications						
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
		BLLBRRY	29	26	90%	50
CINSW	3	0	0%	101	35	66
HNELHD	14	14	100%	28	21	8
ISLHD	0	0	-	-	-	-
JHFMHN	3	3	100%	75	0	75
NBMLHD	2	2	100%	49	25	24
NNSWLHD	3	1	33%	116	52	64
NSLHD	30	30	100%	32	14	18
SCHN	12	9	75%	60	26	34
SESLHD	15	10	67%	81	53	28
SLHD-CCD	8	8	100%	67	26	41
SLHD-RPA	26	26	100%	54	31	23
SVHN	16	13	81%	69	38	31
SWSLHD	15	8	53%	111	75	36
WNSWLHD	9	6	67%	74	35	39
WSLHD	24	13	54%	85	41	45
TOTAL	209	169	81%	54	33	20

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

Ethics Approval (Q1 2024)						
Clinical Trials						
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count	% < 90 Day	Average	Average Research Office Time	Average Researcher Time
		< 90 Day Benchmark	Total Time Benchmark	Total Time (Days)		
BLLBRRY	29	25	86%	50	26	23
CINSW	0	0	-	-	-	-
HNELHD	5	5	100%	29	18	11
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	0	0	-	-	-	-
NNSWLHD	0	0	-	-	-	-
NSLHD	6	6	100%	58	17	41
SCHN	5	5	100%	39	17	23
SESLHD	7	6	86%	56	45	11
SLHD-CCD	3	3	100%	78	25	53
SLHD-RPA	11	11	100%	59	39	20
SVHN	8	6	75%	61	37	24
SWSLHD	4	0	0%	168	108	59
WNSWLHD	0	0	-	-	-	-
WSLHD	6	2	33%	91	38	53
TOTAL	84	63	75%	61	34	27

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
BLLBRRY	0	-	-	27	26	50	2	27	43
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	0	-	-	3	18	25	2	18	35
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	0	-	-	0	-	-	0	-	-
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	0	-	-	0	-	-	6	17	58
SCHN	0	-	-	4	14	39	1	30	42
SESLHD	1	44	53	1	74	41	5	40	60
SLHD-CCD	1	19	85	1	28	71	1	28	78
SLHD-RPA	5	36	56	1	26	57	5	44	62
SVHN	1	32	51	4	42	77	3	31	42
SWSLHD	1	161	194	2	97	191	1	78	95
WNSWLHD	0	-	-	0	-	-	0	-	-
WSLHD	1	38	106	3	52	96	2	17	75
Grand Total	10	48	77	46	32	59	28	31	57

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/07/2023 and 31/03/2024), **by sponsor type**

	Q3 2023			Q4 2023			Q1 2024		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	18	31	51	15	24	41	10	48	77
Commercial Entity	48	30	49	44	34	55	46	32	59
Investigator Initiated	27	27	48	17	22	41	28	31	57
Total	93	29	49	76	26	43	84	26	43

Table 5. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/07/2023 and 31/03/2024).

NSW PHOs	Q3 2023							Q4 2023							Q1 2024						
	Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	27	25	93%	18	24	89%	47	23	21	91%	17	21	91%	47	29	23	79%	23	26	90%	50
CINSW	5	5	100%	15	5	100%	49	5	4	80%	34	4	80%	74	3	1	33%	66	0	0%	101
HNELHD	22	21	95%	14	22	100%	30	32	32	100%	7	32	100%	23	14	14	100%	8	14	100%	28
ISLHD	5	5	100%	18	5	100%	54	0	0	-	-	0	-	-	0	0	-	-	0	-	-
JHFMHN	1	0	0%	50	1	100%	88	4	4	100%	8	4	100%	46	3	0	0%	75	3	100%	75
NBMLHD	3	3	100%	23	1	33%	93	3	3	100%	16	3	100%	45	2	1	50%	24	2	100%	49
NNSWLHD	2	2	100%	7	2	100%	48	1	1	100%	38	1	100%	70	3	2	67%	64	1	33%	116
NSLHD	31	31	100%	14	31	100%	40	39	38	97%	15	39	100%	34	30	27	90%	18	30	100%	32
SCHN	22	21	95%	18	22	100%	46	7	7	100%	17	7	100%	44	12	8	67%	34	9	75%	60
SESLHD	10	9	90%	20	7	70%	73	11	10	91%	16	8	73%	66	15	12	80%	28	10	67%	81
SLHD-CCD	6	5	83%	29	6	100%	52	14	10	71%	32	14	100%	54	8	4	50%	41	8	100%	67
SLHD-RPA	44	42	95%	17	44	100%	33	43	42	98%	15	43	100%	34	26	23	88%	23	26	100%	54
SVHN	16	12	75%	29	13	81%	55	31	20	65%	47	22	71%	78	16	12	75%	31	13	81%	69
SWSLHD	12	12	100%	13	10	83%	53	16	16	100%	15	11	69%	74	15	12	80%	36	8	53%	111
WNSWLHD	4	4	100%	22	4	100%	69	4	3	75%	27	2	50%	79	9	6	67%	39	6	67%	74
WSLHD	24	22	92%	26	21	88%	70	16	12	75%	35	12	75%	78	24	13	54%	45	13	54%	85
TOTAL	234	219	94%	19	218	93%	48	249	223	90%	21	223	88%	54	209	158	76%	21	169	88%	54



Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope

Site-specific assessment (SSA) applications

Frequency

Quarterly

Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

Exclusions

- Application Type = Low and negligible risk
- Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 1 2024**) are shown in **Table 6**. During the reporting period, **376** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **51** days.

Of these **376** studies, **194** were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q1 2024)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	1	1	100%	18	14	4	0	0
Calvary	9	9	100%	12	10	2	1	0
CCLHD	7	7	100%	33	9	8	0	16
FWLHD	0	0	-	-	-	-	-	-
HNELHD	22	20	91%	25	10	5	2	11
ISLHD	4	4	100%	8	3	5	2	0
JHFMHN	0	0	-	-	-	-	-	-
MLHD	2	2	100%	21	11	4	1	7
MNCLHD	9	9	100%	30	9	5	9	16
NBMLHD	6	4	67%	77	28	46	3	3
NNSWLHD	2	2	100%	57	14	1	4	43
NSLHD	48	46	96%	39	18	7	4	13
NSWHPTH	7	0	0%	132	40	36	1	55
SCHN	6	3	50%	67	21	17	1	29
SESLHD	43	38	88%	42	9	12	0	20
SLHD-CCD	18	18	100%	26	9	7	12	4
SLHD-RPA	50	49	98%	32	13	7	9	11
SNSWLHD	2	0	0%	165	165	0	0	0
SVHN	22	16	73%	54	11	9	1	33
SWSLHD	48	9	19%	102	55	14	1	33
WNSWLHD	5	3	60%	48	9	18	0	21
WSLHD	65	45	69%	50	12	10	5	28
TOTAL	376	286	76%	51	20	10	4	21

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q1 2024) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	7	7	100%	12	10	2	1	0
CCLHD	4	4	100%	26	11	5	0	10
FWLHD	0	0	-	-	-	-	-	-
HNELHD	6	5	83%	20	7	6	3	7
ISLHD	2	2	100%	4	2	2	2	0
JHFMHN	0	0	-	-	-	-	-	-
MLHD	0	0	-	-	-	-	-	-
MNCLHD	6	6	100%	34	13	8	12	12
NBMLHD	2	1	50%	73	6	62	2	5
NNSWLHD	1	1	100%	56	27	1	7	28
NSLHD	22	21	95%	40	21	8	4	11
NSWHPH	1	0	0	70	13	21	3	36
SCHN	2	0	0%	87	17	9	1	62
SESLHD	22	21	95%	41	11	16	0	14
SLHD-CCD	11	11	100%	33	13	9	15	5
SLHD-RPA	29	28	97%	35	15	6	12	13
SNSWLHD	1	0	0%	105	105	0	0	0
SVHN	13	10	77%	51	11	9	1	31
SWSLHD	28	5	18%	104	57	20	1	26
WNSWLHD	3	1	33%	50	13	23	0	14
WSLHD	34	24	71%	43	13	11	5	18
TOTAL	194	147	76%	51	22	12	5	17

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	2	8	8	5	10	14	0	-	-
CCLHD	0	-	-	1	5	6	3	13	33
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	1	2	16	2	4	5	3	10	32
ISLHD	1	0	3	1	4	5	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	0	-	-
MNCLHD	3	22	38	1	13	21	2	0	33
NBMLHD	0	-	-	2	6	73	0	-	-
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	7	36	59	8	12	21	7	16	43
NSWHPTH	0	-	-	0	-	-	0	-	-
SCHN	1	24	95	1	9	78	0	-	-
SESLHD	6	5	46	11	13	36	4	12	45
SLHD-CCD	2	28	37	9	10	32	0	-	-
SLHD-RPA	6	23	49	18	14	31	5	10	33
SNSWLHD	0	-	-	0	-	-	1	105	105
SVHN	2	8	19	6	11	46	5	12	69
SWSLHD	6	71	137	17	51	84	5	61	131
WNSWLHD	3	13	50	0	-	-	0	-	-
WSLHD	5	27	73	23	12	30	5	8	65
Total	48	28	63	105	20	42	40	20	60

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q3 2023			Q4 2023			Q1 2024		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	50	12	43	69	24	51	48	28	63
Commercial Entity	118	9	28	140	17	35	105	20	42
Investigator Initiated	60	19	44	59	15	53	40	20	60
Total	228	12	35	268	18	47	193	22	47

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/07/2023 and 31/03/2024).

LHD	Q3 2023							Q4 2023							Q1 2024						
	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	3	1	0.3333	64	1	33%	158	0	0	-	-	0	-	-	1	1	1	14	1	100%	18
CALVARY	7	6	86%	8	7	100%	11	12	9	75%	9	12	100%	11	9	8	89%	10	9	100%	12
CCLHD	11	10	91%	5	11	100%	13	11	9	82%	9	10	91%	28	7	6	86%	9	7	100%	33
FWLHD	1	1	100%	11	1	100%	11	0	0	-	-	0	-	-	0	0	-	-	0	-	-
HNELHD	33	21	64%	13	33	100%	27	50	27	54%	14	49	98%	30	22	18	82%	10	20	91%	25
ISLHD	17	17	100%	2	17	100%	5	19	19	100%	1	18	95%	8	4	4	100%	3	4	100%	8
JHFMHN	2	0	0%	46	2	100%	51	0	0	0	0	0	-	-	0	0	-	-	0	-	-
MLHD	4	3	75%	11	4	100%	18	10	9	90%	6	10	100%	32	2	2	100%	11	2	100%	21
MNCLHD	6	6	100%	6	6	100%	19	8	7	88%	7	7	88%	27	9	6	67%	9	9	100%	30
NBMLHD	7	1	14%	36	7	100%	53	20	7	35%	32	17	85%	58	6	2	33%	28	4	67%	77
NNSWLHD	9	6	67%	13	9	100%	22	4	3	75%	5	4	100%	39	2	1	50%	14	2	100%	57
NSLHD	47	27	57%	14	44	94%	30	60	36	60%	14	53	88%	38	48	26	54%	18	46	96%	39
NSWHPH	12	1	8%	35	10	83%	61	2	0	0%	28	1	50%	74	7	2	29%	40	0	0%	132
SCHN	21	17	81%	9	21	100%	34	58	47	81%	9	52	90%	35	6	2	33%	21	3	50%	67
SESLHD	38	22	58%	13	26	68%	49	52	34	65%	14	41	79%	48	43	36	84%	9	38	88%	42
SLHD-CCD	16	14	88%	5	16	100%	25	29	23	79%	8	29	100%	25	18	12	67%	9	18	100%	26
SLHD-RPA	60	51	85%	6	60	100%	24	93	75	81%	8	90	97%	26	50	33	66%	13	49	98%	32
SNSWLHD	0	0	-	-	0	-	-	2	1	50%	38	1	50%	46	2	0	0%	165	0	0%	165
SVHN	41	32	78%	19	28	68%	60	34	25	74%	10	23	68%	54	22	18	82%	11	16	73%	54
SWSLHD	47	8	17%	28	39	83%	50	43	6	14%	54	14	33%	92	48	4	8%	55	9	19%	102
WNSWLHD	8	8	100%	5	8	100%	11	8	5	63%	13	7	88%	22	5	4	80%	9	3	60%	48
WSLHD	71	63	89%	9	63	89%	34	77	65	84%	9	63	82%	40	65	48	74%	12	45	69%	50
Total	461	315	68%	14	413	90%	36	592	407	69%	14	508	86%	40	376	233	62%	20	286	76%	51

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:(02)93919920) | james.cokayne@health.nsw.gov.au

Ambika MV Murthy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\)9269 5558](tel:(02)92695558) | Ambika.Murthy@health.nsw.gov.au

Deb Aldridge

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7462](tel:(02)94617462) | deborah.aldridge@health.nsw.gov.au